Abstract 421P
Background
The objective of this retrospective study was to look at the impact of CDK4/6i and other novel agents among pts with stage IV denovo HR+ve/HER2-ve breast cancer (BC).
Methods
We utilized a federated network of de-identified health data representing approximately 145 million pt lives available through the TriNetX Research Network. We identified pts with HR+ve/HER2-ve stage IV denovo BC treated with CDK4/6i diagnosed between Jan 2004 and Jan 2024. Propensity score matching analysis by age and site of metastases was carried out. OS was computed using the Kaplan Meier product limit method. The index event is the date of diagosis diagnosis.
Results
7025 pts with stage IV Denovo HR+ve/HER2-ve were identified of whom 940 (13.4%), 4,287 (60.4%) and 2,502 (35.6%) pts received Ribo, Palbo and Abema respectively. 57 (0.81%) received elacestrant (ELA), 2,720 (38.3%) received fulvestrant (FUL), 112 (1.6%) received PARPi and 165 (2.35%) received an antibody drug conjugate (ADC). Median OS was 6.8yrs. Median OS was similar between Ribo and Abema (HR 1.27; 95%CI (0.93, 1.73) p=0.13). Compared to pts receiving Palbo, pts who received Ribo (HR 0.76; 95%CI (0.58, 0.99) p=0.04) and Abema (HR 0.58; 95%CI (0.48,0.69) p<0.0001) had a better median OS respectively.720 pts received >1 CDK4/6i (210 received Palbo + Ribo, 125 Ribo + Abema, 440 Abema + Palbo). Median OS was 6.3y and 9.4y (HR 1.61; 95%CI (1.33,1.95) p<0.0001) respectively among pts who received 1 vs >1 CDK4/6i. OS was significantly longer among pts who received ELA vs those who did not (HR: 0.30 95% CI (0.16,0.57) p=0.0001) and among pts who received ELA + ful vs those who received FUL alone (p=0.0022). Among pts who received ELA 39.1% received CDK4/6i for >12m. Pts who received ELA 1-yr OS from the start of ELA was 77.1% and 60.6% among pts who received CDK4/6i >12m and <12m respectively (p= 0.56). OS was significantly longer among pts who received an ADC compared to those who did not (HR: 0.48 95% CI (0.33,0.72), p= 0.0002).Among pts who received PARPi 85% and 15% received it pre and post CDK4/6i respectively. Median OS among pts who received PARPi was 5.4y.
Conclusions
Among pts with stage IV denovo HR+ve/HER2-ve BC treated with a CDK4/6i novel agents such as oral SERDS and ADCs have improved prognostic outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
author.
Funding
Has not received any funding.
Disclosure
S. Dawood: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Lilly, Merck, Gilead; Financial Interests, Personal, Invited Speaker: Roche, MSD, BMS, Pfizer, Lilly, AstraZeneca, caris; Financial Interests, Institutional, Research Grant: MSD, Amgen; Non-Financial Interests, Member: ASCO, ESMO. All other authors have declared no conflicts of interest.
Resources from the same session
545P - HIBRID: Histology and ct-DNA based risk-stratification with deep learning
Presenter: Chiara Loeffler
Session: Poster session 15
546P - An artificial intelligence system integrating deep learning-proteomics, pathomics and clinicopathological features to determine risk of T1 colorectal cancer metastasis to lymph node
Presenter: Yijiao Chen
Session: Poster session 15